XLO - Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
2024-04-04 16:57:58 ET
Summary
- Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12.
- Xilio Therapeutics out-licensed their modified IL-12 to Gilead, but I wouldn't be surprised if Werewolf Therapeutics also has a competitive modified IL-12, with WTX-330.
- Werewolf Therapeutics is reporting data from its clinical trials of WTX-124 and WTX-330 this half (H1'24), providing near-term catalysts.
Werewolf Therapeutics, Inc. ( HOWL ) develops modified cytokines, called Indukines, with potential to treat cancer. I rated HOWL a strong buy back in December 2023, based on encouraging data seen with their modified interleukin-2 (IL-2), WTX-124, the potential of the rest of the pipeline and their cash-efficient operation. There is a near-term readout from a major competitor, Medicenna Therapeutics Corp. ( MDNAF , I'm long), and there has been business development in the cytokine space too, with Gilead Sciences, Inc. ( GILD ) in-licensing Xilio Therapeutics, Inc. ( XLO ), modified interleukin-12 (IL-12). The competition is thus ever present, a major competitor readout is near, HOWL trades further over cash giving it more room to fall, and so I now rate HOWL a Buy, instead of a Strong Buy....
Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space